H.C. Wainwright analyst Patrick Trucchio initiated coverage of Voyager Therapeutics with a Buy rating and $30 price target. Voyager is an emerging leader in neurogenetic medicines, focused on novel treatment approaches to diseases of the central nervous system with validated targets and biomarkers, the analyst tells investors in a research note. The firm expects the company’s wholly-owned and partnered programs to generate at least four Investigational new drug filings in 2024 and 2025, potentially generating key clinical proof-of-biology data as early as 2025, further validating the platform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VYGR:
- Voyager Therapeutics appoints Toby Ferguson as CMO
- Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
- Voyager Therapeutics initiated with a Buy at Citi
- Voyager Therapeutics reports Q4 EPS $1.25, consensus (29c)
- Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
